Prognostic significance of B‑cell lymphoma 2 expression in acute leukemia: A systematic review and meta‑analysis

Liu,Yanfeng; He,Pengcheng; Liu,Feng; Shi,Lili; Zhu,Huachao; Cheng,Xiaoyan; Zhao,Jing; Wang,Yuan; Zhang,Mei

doi:10.3892/mco.2014.248

Prognostic significance of B‑cell lymphoma 2 expression in acute leukemia: A systematic review and meta‑analysis

Authors:
- Yanfeng Liu
- Pengcheng He
- Feng Liu
- Lili Shi
- Huachao Zhu
- Xiaoyan Cheng
- Jing Zhao
- Yuan Wang
- Mei Zhang
View Affiliations

Affiliations: Department of Hematology, The First Affiliated Hospital, School of Medicine, Xi'an Jiaotong University, Xi'an, Shaanxi 710061, P.R. China
Published online on: January 24, 2014 https://doi.org/10.3892/mco.2014.248
Pages: 411-414

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

A number of studies have provided estimates of the correlation between B‑cell lymphoma 2 (Bcl‑2) expression and its clinical significance in acute leukemia (AL); however, the results have been heterogeneous. In order to clarify the prognostic significance of Bcl‑2 status in patients with AL, a systematic review and meta‑analysis of 5 published studies including a total of 665 subjects was performed. The reported frequency of Bcl‑2 expression was 0‑99.00%. Bcl‑2‑positive patients had a higher median white blood cell count compared to Bcl‑2‑negative patients. Additionally, Bcl‑2‑negative patients had >2‑fold higher odds of achieving complete remission (CR) compared to Bcl‑2‑positive patients. The summary hazard ratio of Bcl‑2 negativity̸positivity for CR was 0.62 [95% confidence interval: 0.53‑0.81, P<0.001]. Although this meta‑analysis was based on data abstracted from observational studies, our results may justify the use of risk‑adapted therapeutic strategies for AL according to the Bcl‑2 expression status.

View Figures

View References

1.	Rubnitz JE, Gibson B and Smith FO: Acute myeloid leukemia. Hematol Oncol Clin North Am. 24:35–63. 2010. View Article : Google Scholar
2.	Jemal A, Siegel R, Xu J and Ward E: Cancer statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar
3.	Harrison CJ, Hills RK, Moorman AV, et al: Cytogenetics of childhood acute myeloid leukemia: United Kingdom Medical Research Council Treatment trials AML 10 and 12. J Clin Oncol. 28:2674–2681. 2010. View Article : Google Scholar : PubMed/NCBI
4.	Grimwade D: The clinical significance of cytogenetic abnormalities in acute myeloid leukaemia. Best Pract Res Clin Haematol. 14:497–529. 2001. View Article : Google Scholar : PubMed/NCBI
5.	Martin B, Paesmans M, Berghmans T, et al: Role of Bcl-2 as a prognostic factor for survival in lung cancer: a systematic review of the literature with meta-analysis. Br J Cancer. 89:55–64. 2003. View Article : Google Scholar : PubMed/NCBI
6.	Leber B, Lin J and Andrews DW: Still embedded together binding to membranes regulates Bcl-2 protein interactions. Oncogene. 29:5221–5230. 2010. View Article : Google Scholar : PubMed/NCBI
7.	Chipuk JE, Moldoveanu T, Llambi F, Parsons MJ and Green DR: The BCL-2 family reunion. Mol Cell. 37:299–310. 2010. View Article : Google Scholar : PubMed/NCBI
8.	Adams JM and Cory S: The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene. 26:1324–1337. 2007. View Article : Google Scholar : PubMed/NCBI
9.	Soundararajan S, Chen W, Spicer EK, Courtenay-Luck N and Fernandes DJ: The nucleolin targeting aptamer AS1411 destabilizes Bcl-2 messenger RNA in human breast cancer cells. Cancer Res. 68:2358–2365. 2008. View Article : Google Scholar : PubMed/NCBI
10.	Khor LY, Moughan J, Al-Saleem T, et al: Bcl-2 and Bax expression predict prostate cancer outcome in men treated with androgen deprivation and radiotherapy on radiation therapy oncology group protocol 92-02. Clin Cancer Res. 13:3585–3590. 2007. View Article : Google Scholar : PubMed/NCBI
11.	Bender A, Opel D, Naumann I, et al: PI3K inhibitors prime neuroblastoma cells for chemotherapy by shifting the balance towards pro-apoptotic Bcl-2 proteins and enhanced mitochondrial apoptosis. Oncogene. 30:494–503. 2011. View Article : Google Scholar
12.	Guyatt GH, Oxman AD, Vist GE, et al GRADE Working Group: GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 336:924–926. 2008. View Article : Google Scholar : PubMed/NCBI
13.	Parmar MK, Torri V and Stewart L: Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med. 17:2815–2834. 1998. View Article : Google Scholar : PubMed/NCBI
14.	Hotta K, Matsuo K, Ueoka H, Kiura K, Tabata M and Tanimoto M: Meta-analysis of randomized clinical trials comparing cisplatin to carboplatin in patients with advanced non-small-cell lung cancer. J Clin Oncol. 22:3852–3859. 2004. View Article : Google Scholar
15.	Begg CB and Mazumdar M: Operating characteristics of a rank correlation test for publication bias. Biometrics. 50:1088–1101. 1994. View Article : Google Scholar
16.	Egger M, Davey Smith G, Schneider M and Minder C: Bias in meta-analysis detected by a simple, graphical test. BMJ. 315:629–634. 1997. View Article : Google Scholar : PubMed/NCBI
17.	Feng JH, Guo XP, Chen YY, Wang ZJ, Cheng YP and Tang YM: Prognostic significance of IDH1 mutations in acute myeloid leukemia: a meta-analysis. Am J Blood Res. 2:254–264. 2012.PubMed/NCBI
18.	Zhao XQ, Li GS, Guo WJ, et al: Expression of bcl-2 and bax protein and clinical significance in children with acute leukemia. Chin J Contemp Pediatr. 1:193–195. 1999.(In Chinese).
19.	Campos L, Rouault JP, Sabido O, et al: High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy. Blood. 81:3091–3096. 1993.PubMed/NCBI
20.	Karakas T, Maurer U, Weidmann E, Miething CC, Hoelzer D and Bergmann L: High expression of bcl-2 mRNA as a determinant of poor prognosis in acute myeloid leukemia. Ann Oncol. 9:159–165. 1998. View Article : Google Scholar : PubMed/NCBI
21.	Uckun FM, Yang Z, Sather H, et al: Cellular expression of antiapoptotic BCL-2 oncoprotein in newly diagnosed childhood acute lymphoblastic leukemia: a Children’s Cancer Group Study. Blood. 89:3769–3777. 1997.
22.	Maung ZT, MacLean FR, Reid MM, et al: The relationship between bcl-2 expression and response to chemotherapy in acute leukaemia. Br J Haematol. 88:105–109. 1994. View Article : Google Scholar : PubMed/NCBI
23.	Fakler M, Loeder S, Vogler M, et al: Small molecule XIAP inhibitors cooperate with TRAIL to induce apoptosis in childhood acute leukemia cells and overcome Bcl-2-mediated resistance. Blood. 113:1710–1722. 2009. View Article : Google Scholar : PubMed/NCBI
24.	Beitinjaneh A, Jang S, Roukoz H and Majhail NS: Prognostic significance of FLT3 internal tandem duplication and tyrosine kinase domain mutations in acute promyelocytic leukemia: a systematic review. Leuk Res. 34:831–836. 2010. View Article : Google Scholar : PubMed/NCBI
25.	Yanada M, Matsuo K, Suzuki T, Kiyoi H and Naoe T: Prognostic significance of FLT3 internal tandem duplication and tyrosine kinase domain mutations for acute myeloid leukemia: a meta-analysis. Leukemia. 19:1345–1349. 2005. View Article : Google Scholar : PubMed/NCBI